About Exocyst complex component 3-like protein
Exocyst complex component 3-like protein (EXOC3L1) is a protein
from Homo sapiens identified by UniProt accession
Q86VI1, 746 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | Exocyst complex component 3-like protein |
|---|
| UniProt accession | Q86VI1 |
|---|
| Gene | EXOC3L1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 746 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86VI1-F1 | alphafold | PREDICTED | 87.00 | — |
Amino-acid sequence (746 residues)
MDSAAKDEMQ PALSPGPEWP EQERAEQLAR GAALKWASGI FYRPEQLARL GQYRSREVQR TCSLESRLKS VMQSYLEGVQ TGVWQLAQAI EVVQGTREAL SQARGLLQGM SQALQTLEPL RERVAQHKQL QALSHLLPRL RAVPAAVSHT QTLIDGQQFL EAYVSLRELE QLREDTWAPL GGLELPVFQG LDLLFEALGQ AVEAAAGAAG KLAREDPALL VAAVRVAEVE TGRTTPLGQV PRDWRQRCLR ALQEGLEQAH FGSPLLPAPG ALPGWLEALR VALPVELATA EALVAPCCPP QYNVVQLWAH TLHSGLRRSL QNLLAGPELE AADAFALLHW ALHVYLGQEM MGSLELGPEA DVSQLEPLLT LENIEQLEAT FVANIQASVS QWLQNALDGE VAEWGREHGP NTDPSGSYYS PMPAIVLQIL EENIRVASLV SESLQQRVHG MALSELGTFL RSFSDALIRF SRDHFRGKSM APHYVPYLLA ALNHKSALSS SVSVLQLDGA PSGALAPVEA ALDELQRRIY RLVLEALQAE LQPLFADLPS RQWLSSPELL QSVCERTGRF CRDFWRVRNP TVQLLLAEAE RAVVLQYLSA LMQGRLVCRG ADERTQAAER LRHDAAQLQQ LFLSLGLEEN AHCAPVLLAL RELLNLRDPA LLGLEVAGLR QQFPDVSEDH VSALLGLRGD LSREQHLAAL SSLQAALPPS PRASRRVLFS LVPAPALAPA SCLPSGSCAR ALLLAE
Explore Exocyst complex component 3-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets